• Home Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548 Akebia Therapeutics.

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548 Akebia Therapeutics.

‘We are on track to execute our technique to develop a easy, oral therapy with the potential to provide patients a predictable, sustained and meaningful improvement in their hemoglobin levels,’ said John P. Butler, Chief and President Executive Officer of Akebia. ‘The completion of enrollment inside our Phase 2b research for AKB-6548 is an important milestone for Akebia, and we will work to develop a clinical data package that can position AKB-6548 as the best-in-class fresh therapy for the treatment of anemia secondary to CKD.’ The Phase 2b randomized, double-blind, placebo-controlled study is made to evaluate the security and efficacy of AKB-6548 for the treating anemia connected with CKD in individuals who are not on dialysis. There are 209 patients enrolled in the study at more than 50 sites across the United States.This is why it’s not surprising to see teenagers usually developing acne. However, teens aren’t the just ones who’ve to offer with this problem. In fact, a large %age of adults also develop acne at onetime or another within their adult lives. Acne can cause social stress and anxiety and depression for all those suffering from it. This is normally why it’s vital to treat this issue to avoid such unnecessary pain. Although there is no single best way to eliminate acne, below are a few pointers to help you battle off this annoying problem.